The Bioassays Conference Stream explores the critical role of statistical analysis, design of experiments (DOE), and assay validation in bioassay development. Attendees will learn strategic approaches to optimizing bioassays, measuring assay capability, and implementing lifecycle monitoring with graphical and quantitative tools. With a focus on emerging therapeutic modalities—including cell and gene therapies, immunotherapies, and antibody-drug conjugates—this forum brings together industry and academic experts to discuss regulatory perspectives, cutting-edge case studies, and novel bioassay solutions. Join us to gain practical insights into overcoming challenges in bioassay development, validation, transfer, and maintenance.

Conferences Include:

Keynote Presentations:

Ligand Qualification Strategy for Abeta Peptides for Alzheimer Therapeutics
Piyush Vyas, PhD, Director, Bioassay & Protein Therapeutics, Eli Lilly & Co.

Autologous TIL Products: Statistical Considerations
Steven Walfish, Principal CMC Statistician, Iovance Biotherapeutics